SEMA6D 抗体

+ +

•  

   

     Gel: 6%SDS-PAGE, Lysate: 40 μg, Lane: LOVO cell lysate, Primary antibody: P12149(SEMA6D  Antibody) at dilution 1/700, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 5 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P12149(SEMA6D  Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

SEMA6D (Semaphorin-6D) is a transmembrane protein belonging to the semaphorin family, which plays diverse roles in cell signaling, including axon guidance, immune regulation, and tissue development. It contains a conserved Sema domain, a PSI (plexin-semaphorin-integrin) domain, and an intracellular PDZ-binding motif, enabling interactions with receptors like Plexin-A1 and Trem2. SEMA6D is implicated in modulating immune synapses, T-cell activation, and bone homeostasis, with emerging links to cancer progression and autoimmune disorders.

SEMA6D antibodies are essential tools for studying its expression, localization, and function in physiological and pathological contexts. These antibodies are typically generated against specific epitopes within the extracellular Sema domain or intracellular regions, enabling applications such as Western blotting, immunohistochemistry, flow cytometry, and co-immunoprecipitation. Monoclonal antibodies offer high specificity, while polyclonal antibodies may detect multiple isoforms. Recent studies utilize SEMA6D antibodies to explore its dual role in cancer—acting as a tumor suppressor in some contexts (e.g., inhibiting angiogenesis) or promoting metastasis via immune evasion mechanisms. They also help dissect SEMA6D's involvement in neurodevelopmental disorders and osteoclast differentiation. Validation of antibody specificity using knockout controls or siRNA-mediated knockdown is critical, as cross-reactivity with other semaphorins (e.g., SEMA6A/B/C) remains a potential challenge. Ongoing research leverages these antibodies to develop therapeutic strategies targeting SEMA6D-associated pathways in diseases like rheumatoid arthritis and glioblastoma.